Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: 36 Dead From Breast Implant-Associated Lymphoma Since 2019, Hundreds Sickened

Agency also verifies Breast-Q module as a tool to help assess women's satisfaction with implanted devices

Executive Summary

The US FDA reports the numbers on women globally who've died or been sickened by two types of breast implant illnesses.

You may also be interested in...



Breast Implant Patient Preferences Topic Of New FDA Study

The US agency’s study will look at how the potential cancer risk tied to textured breast implants, as well as other factors, play into how patients decide what type of implants to get.

FDA Strengthens Safety Requirements For Breast Implants

The US FDA has approved new labeling for all legally marketed breast implants that includes a boxed warning of potential risks. The agency also released updated information on the status of implant manufacturer post-approval studies.

FDA: Some Mesh Brands May Lead To More Complications In Breast Reconstruction Patients

Patients who receive breast reconstructive surgery using some brands of acellular dermal matrix seem to have a higher risk of major complications than those whose surgeries did not use the mesh, says a safety alert from the US FDA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT142638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel